LBO-002 Efruxifermin significantly reduced liver fibrosis in MASH patients with F2-F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)

作者：Stephen A. Harrison, Juan P. Frías, Guy Neff, Gary A. Abrams, Kathryn Jean Lucas, William Sánchez, Sudhanshu Gogia, Muhammad Y. Sheikh, Cynthia Behling, Pierre Bédossa, Lan Shao, Doreen Chan, Erica Fong, Brittany de Temple, Matthew Minerva, Kimberly L. Barrett, Reshma Shringarpure, Erik R. Tillman, Tim Rolph, Andrew Cheng, Vlad Ratziu, Kitty Yale · 发表于：Journal of Hepatology · 年份：2024 · DOI：10.1016/s0168-8278(24)00437-9 · 被引用次数：8 · 研究领域：Liver Disease Diagnosis and Treatment